- Conditions
- Pre-Exposure Prophylaxis of HIV Infection
- Interventions
- Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 253 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 338
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Human Immunodeficiency Virus, Virus Shedding
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Human Immunodeficiency Virus
- Interventions
- emtricitabine/tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- HIV-1 Infection
- Interventions
- E/C/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 3
- States / cities
- Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida
- Conditions
- HIV Infections, Aging
- Interventions
- biopsy
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- HIV-1 Infection
- Interventions
- Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 14 more
- Conditions
- HIV/AIDS, Gender, Behavior and Behavior Mechanisms
- Interventions
- TDF/FTC
- Drug
- Lead sponsor
- Hektoen Institute for Medical Research
- Other
- Eligibility
- 15 Years to 24 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- HIV Prevention
- Interventions
- Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC), Placebo
- Drug · Other
- Lead sponsor
- Oak Crest Institute of Science
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- HIV-1-infection
- Interventions
- GS-3242, BVY, Standard of Care
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 21
- States / cities
- Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Immunodeficiency Virus Type 1, Human
- Interventions
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC, DRV/COBI FDC, FTC/TDF FDC, D/C/F/TAF FDC - Matching Placebo, FTC/TDF FDC Matching Placebo, DRV/COBI FDC Matching Placebo
- Drug
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 725 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more
- Conditions
- HIV-1-Infection
- Interventions
- ISL/LEN, Antiretroviral Combinations
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more
- Conditions
- HIV
- Interventions
- ritonavir, darunavir, emtricitabine [FTC]/tenofovir [TDF], atazanavir
- Drug
- Lead sponsor
- Tibotec, Inc
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Glastonbury, Connecticut • Washington D.C., District of Columbia + 12 more
- Conditions
- HIV Infections
- Interventions
- Emtricitabine, Enfuvirtide, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more
- Conditions
- Human Immunodeficiency Virus Infection
- Interventions
- lopinavir/ritonavir (LPV/r), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), raltegravir (RAL)
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Atlantis, Florida + 11 more
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Antiretrovirals
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 12 Years to 24 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • New Orleans, Louisiana
- Conditions
- HIV-1 Infection
- Interventions
- FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- BMS-955176, EFV, TDF/FTC
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Los Angeles, California • DeLand, Florida + 5 more
- Conditions
- HIV Infections
- Interventions
- Truvada, Atazanavir, Ritonavir
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Foster City, California
- Conditions
- HIV-1-infection
- Interventions
- Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, SBR
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 2
- States / cities
- Berkeley, Michigan • Annandale, Virginia
- Conditions
- HIV-1 Infection
- Interventions
- ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 61
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 48 more
- Conditions
- Amphetamine-Related Disorders, HIV, HIV Infections
- Interventions
- Truvada, CM
- Drug · Behavioral
- Lead sponsor
- Friends Research Institute, Inc.
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HIV Infections
- Interventions
- Tenofovir disoproxil fumarate/Emtricitabine, Lopinavir/Ritonavir
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Atlanta, Georgia
- Conditions
- HIV Infections
- Interventions
- VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 34
- States / cities
- Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more